Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F24%3A10474998" target="_blank" >RIV/00064203:_____/24:10474998 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/24:10474998
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=T7zVg.DN6-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=T7zVg.DN6-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2023012109" target="_blank" >10.1182/bloodadvances.2023012109</a>
Alternative languages
Result language
angličtina
Original language name
Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Original language description
Since 2022 large B-cell lymphoma with IRF4-rearrangment (LBCL-IRF4+) has been recognized as a definite entity by the World Health Organization (WHO) classification of hematolymphoid tumors. It is characterized by a follicular and/or diffuse growth pattern as well as a strong expression of IRF4, which is due to translocation of IRF4 with an immunoglobulin gene. Essential and desirable diagnostic criteria are set by the WHO including clinical, morphological, immunophenotypical and molecular- genetic parameters. Given that most LBCL-IRF4+ patients are children and young people, the rarity of this lymphoma and lack of any prospective trials, most data on LBCL-IRF4+ come from small reports. Thus, two of the largest childhood non-Hodgkin lymphoma (NHL) consortia, the European Intergroup for Childhood NHL (eicnhl) and the international Berlin-Frankfurt-Münster (i-BFM) Group, designed a retrospective multinational study of LBCL-IRF4+ in children and young people. Here we present data from this series, the largest reported to date.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Advances
ISSN
2473-9529
e-ISSN
2473-9537
Volume of the periodical
8
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
1509-1514
UT code for WoS article
001214951700001
EID of the result in the Scopus database
2-s2.0-85188738515